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Abstract
Introduction: Triple negative breast cancer (TNBC) has a poorer survival, despite a higher response rate to neoadjuvant
chemotherapy. The purpose of this study was to identify the predictive or prognostic value of Ki-67 among patients
with TNBC treated with neoadjuvant chemotherapy, and the role of Ki-67 in further classification of TNBC.
Methods: A total of 105 TNBC patients who received neoadjuvant docetaxel/doxorubicin chemotherapy were
included in the present study. Pathologic complete response (pCR) rate, relapse-free survival (RFS), and overall
survival (OS) were compared according to the level of Ki-67.
Results: pCR was observed in 13.3% of patients. TNBC with high Ki-67 expression (≥10%) showed a higher pCR rate
to neoadjuvant chemotherapy than TNBC with low Ki-67 expression. None of the low Ki-67 group achieved pCR
(18.2% in the high Ki-67 group vs. 0.0% in the low Ki-67 group, P = 0.019). However, a high Ki-67 expression was
significantly associated with poor RFS and OS in TNBC, despite a higher pCR rate (P = 0.005, P = 0.019, respectively).
In multivariate analysis, high Ki-67 was an independent prognostic factor for RFS in TNBC (hazard ratio = 7.82, P =
0.002). The high Ki-67 group showed a similar pattern of recurrence with overall TNBC, whereas the low Ki-67 group
demonstrated a relatively constant hazard rate for relapse.
Conclusions: TNBC with high Ki-67 was associated with a more aggressive clinical feature despite a higher pCR
rate. High proliferation index Ki-67 can be used for further classification of TNBC into two subtypes with different
responses and prognosis.
Introduction
Triple negative breast cancer (TNBC) demonstrates
poor prognosis because of aggressive tumor biology, and
lack of targeted agents such as trastuzumab or tamoxi-
fen [1,2]. TNBC has a pattern of rapid recurrence fol-
lowing diagnosis, and the peak risk of recurrence is
within three years [3,4]. However, after the peak risk
period, the risk of recurrence declines rapidly, and
recurrences seldom occur thereafter [3,4].
Several reports suggested that TNBC was a heteroge-
neous group comprising subtypes with different clinical
outcomes, and further classification of TNBC using cyto-
keratin (CK) 5/6 and epidermal growth factor receptor
(EGFR) was useful to discriminate these subtypes [5-7].
True basal subtype in TNBC, which was defined as CK5/
6 positive or EGFR positive, has shown poorer survival
than CK5/6 and EGFR negative TNBC, which meant that
TNBC could be divided into two subtypes: the aggressive
clone and the less aggressive clone. New clinically applic-
able biologic markers for TNBC need to be developed in
order to identify the patients with poor prognosis, and
alternative treatment options are needed [1].
The proliferation marker Ki-67 has repeatedly been con-
firmed as an independent predictive and prognostic factor
in early breast cancer [8]. Breast cancer with high Ki-67
expression responds better to chemotherapy [9-12], but is
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is similar to the triple negative paradox, which denotes
that TNBC had a poorer survival, despite a higher
response rate to neoadjuvant chemotherapy [4,10,17]. In
addition, TNBC is associated with a higher expression of
Ki-67 than non-TNBC [10,18]. However, to date, the rea-
son for the triple negative paradox is not clear, and there
is little study focusing on the clinical significance of Ki-67
in TNBC. The purpose of this study was to identify the
predictive or prognostic value of Ki-67 among patients
with TNBC treated with neoadjuvant chemotherapy, and
the role of Ki-67 in further classification of TNBC.
Materials and methods
Patients and chemotherapy
Recently, we conducted neoadjuvant docetaxel/doxorubi-
cin chemotherapy in stage II or III breast cancer, and
reported the prognostic and predictive role of the mole-
cular markers [10,19]. The detailed eligibility criteria and
regimen were described in our prior reports [10,19]. In
brief, the patients received three cycles of neoadjuvant
docetaxel/doxorubicin chemotherapy by intravenous
infusion every three weeks. After three cycles of neoadju-
vant chemotherapy, the patients were re-evaluated for
response and underwent curative surgery. Subsequently,
the patients received three more cycles of docetaxel/
doxorubicin as an adjuvant chemotherapy, followed by
hormonal or radiation therapy, if indicated [20]. Between
January 2002 and September 2008, a total of 370 conse-
cutive patients who received neoadjuvant docetaxel/
doxorubicin chemotherapy at Seoul National University
Hospital were included in the present study. Among the
370 patients, 109 patients were classified as TNBC. We
excluded one patient with metaplastic carcinoma because
triple negative phenotype in metaplastic carcinoma
showed a different tumor biology than that of invasive
ductal carcinoma [21]. Three patients were excluded
because Ki-67 was not available due to lack of tissue.
Finally, a total of 105 TNBC patients were analyzed. This
study protocol was reviewed and approved by the Institu-
tional Review Board of the Seoul National University
Hospital (approval number: H-1003-058-313). Because
this study was performed using a total of 370 consecutive
patients in our database, and involved no more than
minimal risk for the subjects, the Institutional Review
Board approved our request for the waiver of informed
consent. Recommendations of the Declaration of Hel-
sinki for biomedical research involving human subjects
were also followed.
Immunohistochemistry
We performed an immunohistochemistry (IHC) using
tissues obtained before treatment. Estrogen receptor
(ER), progesterone receptor (PR), human epidermal
growth factor receptor 2 (HER2), p53, bcl-2, and Ki-67
expressions were evaluated. IHC was performed as pre-
viously described [14,22]. ER and PR positivity was
defined as ≥10% positive tumor cells with nuclear stain-
ing. HER2 positivity was defined as either HER2 gene
amplification by fluorescent in situ hybridization or
scored as 3+ by IHC [23]. In case of HER2 2(+), fluores-
cent in situ hybridization was performed to determine
HER2 positivity. TNBC was defined as ER(-), PR(-), and
HER2(-), regardless of the expression of EGFR and basal
cytokeratins. Only cytoplasmic staining was scored as
positive for bcl-2, regardless of the intensity of the
stained cells. Cells stained for Ki-67 and p53 were
counted and expressed as a percentage. The percentage
was determined by the number of Ki-67 positive cells
among the total number of counted tumor cells. High
expression of Ki-67 was defined as ≥10%, because 10%
as cutoff provided the best prognosis-prediction results
in our institute [14]. Specimens with no residual invasive
carcinoma in the both breast and lymph nodes were
classified as pathologic complete response (pCR). Resi-
dual ductal carcinoma in situ was also included in the
pCR category [24]. Otherwise the specimens which did
not achieve pCR category were classified as residual
disease
Statistics
Relapse-free survival (RFS) was determined as the inter-
val between the initiation of neoadjuvant chemotherapy
and the date when disease relapse or progression was
first documented, or the date of death from any cause.
Overall survival (OS) was measured from the date
neoadjuvant chemotherapy was initiated to the date of
death.
The significance of the difference in the variables
among two Ki-67 groups was calculated using Chi-square
test or Fisher’s exact test, where appropriate. The Kaplan-
Meier product limit method and the Cox proportional
hazard regression (PHR) model were used for survival
analysis. The multivariate Cox PHR model was used to
develop a prediction model for risk of relapse and death.
Discrimination for survival data was evaluated using the
C statistic with concordance index (C-index) [25,26],
which is similar in concept to the area under the receiver
operating characteristic (ROC) curve in the logistic
model, but is appropriate for censored data. The C-index
is the probability that given two subjects, one who will
develop an event and the other who will not, the model
will assign a higher probability of an event to the former
[25]. In general, the model is considered as good for
C-index value above 0.75.
The log-rank tests were used to compare RFS or OS
between different groups. Hazard function is the instan-
taneous failure rate at time t, which is the probability of
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two-sided, with the level of significance established at
P < 0.05. Statistical analyses were performed using
STATA statistical software version 11.0 (STATA, Col-
lege Station, TX, USA) and R software version 2.10.1
[27]. R package with theDesign, survivalROC, and surv-
comp libraries.
Results
Table 1 shows the baseline characteristics of the 105
patients. pCR was observed in 13.3% of the patients.
With a median follow-up duration of 33.6 months, 33
relapse events occurred, and 20 patients died of disease
progression. Estimated one-, two-, and three-year RFS
rates, as calculated by the Kaplan-Meier method, were
83.8%, 71.6%, and 64.6%, respectively. The median value
of Ki-67 was 20.0% (range = 0.0 to 80.0%, standard
deviation = 23.3).
Response to neoadjuvant chemotherapy by Ki-67
expression status in TNBC
Clinicopathologic characteristics between high and low
Ki-67 groups were not different (Table 1). However,
TNBC with high Ki-67 showed a higher pCR rate to
neoadjuvant chemotherapy than TNBC with low Ki-67,
and none of the patients in the low Ki-67 group
achieved pCR (18.2% in the high Ki-67 group vs. 0.0% in
the low Ki-67 group, P = 0.019). pCR rate was propor-
tionally associated with the level of Ki-67. When analyz-
ing with a cutoff of Ki-67 quartile (Q), the pCR rates
were 0.0% in the first Q, 14.3% in the second Q, 18.2%
in the third Q, and 22.2% in the fourth Q, respectively.
Survival by Ki-67 expression status in TNBC
High Ki-67 expression was significantly associated with
poor RFS and OS in TNBC (Figure 1). Combining pCR
and Ki-67, residual disease (RD) with high Ki-67 showed
poorer RFS than RD with low Ki-67 and pCR with high
Ki-67 (Figure 2). RD with low Ki-67 showed better RFS
than RD with high Ki-67 (P = 0.017). However, there was
no statistical difference in RFS between pCR with high
Ki67 and RD with low Ki-67 (P = 0.449). Univariate ana-
lysis revealed that initial clinical stage, pathologic nodal
stage, histologic grade, and Ki-67 were prognostic factors
in TNBC. However, bcl2 and p53 were not associated
with RFS. In multivariate analysis, Ki-67 was the indepen-
dent prognostic factor for RFS in TNBC (Table 2). High
Ki-67 expression was also significantly associated with
poorer OS in multivariate analysis as well as univariate
analysis (Table S1 in Additional file 1).
The discriminatory ability of the model for RFS was
measured using C statistics. The C-index was 0.83 (95%
confidence interval 0.78 to 0.89), indicating good model
performance. We examined the hazard function for
Table 1 Baseline characteristics of 105 patients
Characteristics Total
No. of Pt
(%)
Low Ki-67
No. of Pt
(%)
High Ki-67
a
No. of Pt
(%)
P-
value
Median age (range)
Age <35 years 18 (17.1) 5 (17.9) 13 (16.9) 0.907
Age ≥35 years 87 (82.9) 23 (82.1) 64 (83.1)
Performance status
ECOG 0 25 (23.8) 7 (25.0) 18 (23.4) 0.686
ECOG 1 78 (74.3) 21 (75.0) 57 (74.0)
ECOG 2 2 (1.9) 0 (0.0) 2 (2.6)
Pathologic
characteristics
Invasive ductal
carcinoma
101 (96.2) 28 (100.0) 73 (94.8) 0.572
Others 4 (3.8) 0 (0.0) 4 (5.2)
Initial clinical stage
IIA 4 (3.8) 1 (3.6) 3 (3.9) 0.985
IIB 19 (18.1) 5 (17.9) 14 (18.2)
IIIA 45(42.9) 11 (39.3) 34 (44.2)
IIIB 18 (17.1) 5 (17.9) 13 (16.9)
IIIC 19 (18.1) 6 (21.4) 13 (16.9)
Inflammatory breast
cancer
No 97 (92.4) 25 (89.3) 72 (93.5) 0.437
Yes 8 (7.6) 3 (10.7) 5 (6.5)
Type of surgery
Breast conserving 44 (41.9) 13 (46.4) 31 (40.3) 0.571
Mastectomy 61 (58.1) 15 (53.6) 46 (59.7)
Radiation therapy
No 11 (10.5) 2 (7.1) 9 (11.7) 0.723
Yes 94 (89.5) 26 (92.9) 68 (88.3)
Nuclear grade
I 1(1.0) 0 (0.0) 1 (1.3) 0.260
II 7 (6.7) 2 (7.1) 5 (6.5)
III 88 (73.3) 24 (85.7) 53 (68.8)
Unknown 20 (19.0) 2 (7.1) 18 (23.4)
Histologic grade
I 0 (0.0) 0 (0.0) 0 (0.0) 0.097
II 23 (21.9) 10 (35.7) 13 (16.9)
III 74 (70.5) 17 (60.7) 57 (74.0)
Unknown 8 (7.6) 1 (3.6) 7 (9.1)
bcl-2
Negative 66 (62.9) 15 (53.6) 51 (66.2) 0.235
Positive 39 (37.1) 13 (46.4) 26 (33.8)
p53
Negative 39 (37.1) 12 (42.9) 27 (35.1) 0.657
Positive 65 (61.9) 16 (57.1) 49 (63.6)
Unknown 1 (1.0) 0 (0.0) 1 (1.3)
pCR
No 91 (86.7) 28 (100.0) 86 (81.8) 0.019
Yes 14 (13.3) 0 (0.0) 14 (18.2)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; pCR, pathologic
complete response.
a High Ki-67 expression was defined as ≥10%.
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functions of relapse in TNBC. TNBC has a pattern of
rapid recurrence following diagnosis, and peak risk of
recurrence was at 12 months. After three years, relapse
did not occur except for one patient. When evaluating
the hazard function by Ki-67 expression status, the high
Ki-67 group showed a similar pattern of recurrence with
overall TNBC, whereas the low Ki-67 group demon-
strated a relatively constant hazard rate for relapse
(Figure 3B).
Discussion
In the present study, we found that TNBC with high
Ki-67 expression had poorer survival than TNBC with
low Ki-67 expression, despite a higher pCR rate.
Furthermore, TNBC with high Ki-67 expression showed
rapid recurrence within three years, whereas TNBC with
low Ki-67 expression showed a near-constant recurrence
rate. Ki-67 could divide TNBC into two different clinical
subtypes.
It is well confirmed that pCR to neoadjuvant che-
motherapy is an independent prognostic factor for survi-
val [28-30]. However, several studies have shown that
TNBC has a higher pCR rate but poorer survival than
non-TNBC [4,10,17]. Like this triple negative paradox,
we found that high Ki-67 in TNBC was associated with
ah i g h e rp C Rr a t ea n dp o o r e rs u r v i v a l .H i g hK i - 6 7 ,
representing high proliferation potential, could explain
the paradoxical feature.
Ki-67 is a cell proliferation-associated antigen that is
expressed in all stages of the cell proliferative cycle
except the G0 (quiescent) phase [31]. Among the prolif-
eration-related markers, Ki-67 is known to be the sim-
plest and a widely used method to assess tumor
proliferation. Several studies have investigated the predic-
tive and prognostic values of Ki-67 in breast cancer
patients receiving neoadjuvant chemotherapy
[9,11,32-39]. High Ki-67 was associated with higher
response rate to neoadjuvant chemotherapy in breast
cancer [9,11,34,35,37], although no association between
high Ki-67 and response rate was also reported
[33,36,39]. Some studies emphasized the change of Ki-67
or postoperative level of Ki-67 in predicting the response
[9,32,33,37,38]. Recently, Jones et al. [9] reported that
higher pre-treatment Ki-67 was significantly more likely
to achieve pCR than lower Ki-67, but was associated with
poor RFS and OS. This was consistent with our results.
However, the role of Ki-67 is still not yet conclusive
because of heterogeneous patient populations, small sam-
ple sizes, and different chemotherapeutic regimens in
previous studies [9,11,33-39].
Generally, tumor responsiveness to chemotherapy is
believed to be associated with longer survival. However,
TNBC, which has a higher Ki-67 level than non-TNBC
Figure 1 Kaplan-Meier curve of (A) relapse-free survival and
(B) overall survival by Ki-67 in triple negative breast cancer.
Figure 2 Relapse-free survival (RFS) as a function of pathologic
response. Residual disease (RD) with high Ki-67 showed poorer RFS
than RD with low Ki-67 and pathologic complete response (pCR)
with high Ki-67.
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[4,10,17]. Tumor responsiveness might not always affect
prolonged survival in a tumor with high Ki-67. We first
found this paradoxical feature in TNBC, and our results
suggest that further classification using Ki-67 levels
might improve the prognostic significance of pCR in
neoadjuvant chemotherapy. Surely, it is not yet certain
whether Ki-67 itself is a causable indicator for the triple
negative paradox or just a mediator for another
unknown factor. Further research to find out direct
association is warranted.
Previous reports indicated that TNBC had a pattern of
early recurrence within the first three years of follow-up;
however, the risk of recurrence significantly decreased
thereafter [3,4]. Our study confirms these findings.
Furthermore, when analyzing hazard rate by Ki-67
status, only TNBC with high Ki-67 demonstrated a pat-
tern of early recurrence, whereas the low Ki-67 sub-
group did not show any pattern at all. This suggests
that an early recurrence pattern of TNBC is ascribed to
the high Ki-67 subgroup which has a high proliferation
potential. TNBC seems to be a heterogeneous group
with at least two different clinical courses. TNBC with
high proliferation potential should be followed-up more
frequently within three years, and could be a candidate
for additional postoperative treatments with different
mechanisms. Additional discriminating markers should
be sought to further refine the classification of TNBC.
The present study has some limitations. First, we did
not examine basal markers, namely, CK5/6 and EGFR,
which are potential classifiers that differentiate TNBC
into an aggressive basal clone and a less aggressive
Table 2 Univariate and multivariate Cox regression analysis of factors associated with relapse-free survival in triple
negative breast cancer
Univariate Multivariate
Variables HR 95% CI P-value HR 95% CI P-value
Age
<35 years 1 -
≥35 years 0.77 0.33 to 1.76 0.529
Performance status
ECOG0 1 -
ECOG1 1.41 0.54 to 3.70 0.483
ECOG2 4.29 0.83 to 22.17 0.082
Initial clinical stage
IIA, IIB 1 1
IIIA 9.75 1.30 to 73.30 0.027 7.51 0.98 to 57.83 0.053
IIIB 9.59 1.18 to 77.94 0.034 7.72 0.92 to 64.93 0.060
IIIC 18.59 2.37 to 146.04 0.005 14.75 1.74 to 125.11 0.014
Pathologic N stage
pN0 1 1
pN1 3.79 1.47 to 9.77 0.006 5.87 2.08 to 16.59 0.001
pN2 4.14 1.33 to 12.88 0.014 4.95 1.45 to 16.91 0.011
pN3 6.51 2.09 to 20.26 0.001 7.54 2.14 to 26.56 0.002
bcl-2
Negative 1 -
Positive 0.87 0.43 to 1.76 0.691
p53
Negative 1 -
Positive 1.05 0.52 to 2.16 0.885
Histologic grade
II 1 1
III 3.37 1.03 to 11.06 0.045 2.04 0.57 to 7.37 0.275
Ki-67
Low Ki-67 1 1
High Ki-67 4.64 1.41 to 15.22 0.011 7.82 2.18 to 28.13 0.002
Continuous
a 1.02 1.01 to 1.03 0.003 -
Abbreviations: CI, confidence interval; HR, hazard ratio.
a Entered as continuous variable.
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determine which will be a better classifier for TNBC
among Ki-67 and basal markers. Second, the pCR rate
of our study (13.3%) was relatively lower than that of
another study [17]. This was because only three cycles
of neoadjuvant chemotherapy were performed and the
tumor size was relatively large.
Conclusions
In conclusion, TNBC with high Ki-67 was associated
with a more aggressive clinical feature despite a higher
pCR rate. Ki-67 could explain the triple negative para-
dox, and Ki-67 can be used for further classification of
TNBC into two subtypes with different prognosis. Our
report suggests that TNBC with residual disease and
high Ki-67 expression should be a candidate for addi-
tional postoperative treatment such as platinum-based
chemotherapy, or clinical trials specifically testing novel
therapies in order to improve the outcome for this high-
risk group of patients. In addition, TNBC with high
Ki-67 should be followed-up more frequently within
three years to guard for any recurrence.
Additional material
Additional file 1: Supplementary Table S1. Univariate and multivariate
Cox regression analysis of factors associated with overall survival in triple
negative breast cancer.
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